Navigation Links
U-M researchers link pathway to breast cancer stem cells
Date:6/1/2009

called perifosine, which inhibits the Akt pathway. Tumors in mice were treated with perifosine or docetaxel, a standard chemotherapy drug. The docetaxel alone showed no effect on the number of cancer stem cells in the tumor. But adding perifosine reduced the cancer stem cell population by up to 90 percent.

What's more, the cells treated with perifosine either with or without docetaxel were less likely to grow a secondary tumor, compared to the cells treated with just docetaxel.

"This is most exciting since perifosine and other drugs that target this pathway are currently in clinical development. If cancer stem cells do contribute to tumor relapse, then adding drugs that target these cells may help to make our current therapies more effective," says study senior author Max S. Wicha, M.D., Distinguished Professor of Oncology and director of the U-M Comprehensive Cancer Center.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
U-M researchers link pathway to breast cancer stem cells
(Date:10/22/2014)... (PRWEB) October 22, 2014 On Saturday, October ... its fourth annual family health and fitness fair ¡Vive tu ... physical activity and good nutrition for better health and wellness ... which is free and open to the public, will be ... Brownsville, from 9:00 am to 1:00 pm. , “¡Vive ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 For Dr. Iris ... make money; it’s an extension of her life’s mission. Her ... venture as the owner of FirstLight HomeCare, make it clear ... important to me that my work makes a difference in ... an entrepreneurial spirit, so after much research, I felt ready ...
(Date:10/22/2014)... The Louis W. Sullivan Institute ... distribute health information technology innovation to transform quality ... development of six key guiding principles of patient-centered ... These are an expansion of the Institute of ... is respectful of and responsive to individual patient ...
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2
... including Parkinson's, Alzheimer's, Diffuse Lewy body disease, and ... Most commonly they become symptomatic due to a ... case of Parkinson's it is dopamine. When the ... impaired, which occurs with oxidation, the eventual results ...
... to diagnose and many a times the diagnosis is ... emerging as a promising technique for early diagnosis of ... facilitating rapid amplification of small amounts of a genome ... Urology Congress in India. Presence of even one ...
... (PPA),is a common ingredient found in many non-prescription cough ... remedies increased the risk of stroke by 23 percent. ... says, "Case reports have linked exposure to PPA to ... ,A hemorrhagic stroke results when an artery wall ruptures ...
... of India has successfully undergone left knee joint replacement by ... "The operation, which started at around 10 a.m., was completed ... satisfaction," Dr. Ranawat said at a press briefing. ``He (Mr. ... now in the recovery room. He is not on any ...
... injectable contraceptive pill has been approved by the Food ... than 99 percent effective when women get the shot ... the pill., ,Lunelle is an alternative to another ... works Like many other birth control pills as it ...
... that more than two-thirds of births in Russia are marred ... clinic is suffering health problems. , ,The number of ... 30 percent last year, said Olga Frolova, head of the ... that the decline is due to the spread of heavy ...
Cached Medicine News:
(Date:10/22/2014)... Oct. 22, 2014  Regulus Therapeutics Inc. ... company leading the discovery and development of ... it has demonstrated human proof-of-concept with a ... evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting ... C virus infection ("HCV").  Interim results from ...
(Date:10/20/2014)... -- Indianapolis interventional medical device maker NICO Corporation ... visualization leader Synaptive Medical announced today ... that they have joined forces to integrate their ... the first of its kind and will make ... BrainPath® interventional access technology and Synaptive,s BrightMatter™ real-time ...
(Date:10/20/2014)...   BioNano Genomics announced today achievement of a ... human data at 30X depth, sufficient for a genome map, ... was established and demonstrated for the IrysChip TM V2, ... and will be rolled out to BioNano,s collaborators and ... this advancement at the American Society for Human Genetics ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... Healthcare Limited [NSE: PIRHEALTH, BSE: 500302] ("Piramal"), announced that ... to the molecular imaging research and development portfolio of ... – Piramal Imaging SA. The portfolio includes rights to ... Phase III clinical trials. First Phase III results will ...
... April 13, 2012 /PRNewswire-USNewswire/ --  John C. Lechleiter, ... Company, was elected chairman of the Pharmaceutical Research and ... annual meeting. Also elected were Celgene Corporation President, CEO, ... PhRMA Board of Directors, and Ian C. Read, president ...
Cached Medicine Technology:Piramal Healthcare Limited Acquires Molecular Imaging Development Portfolio of Bayer Pharma 2Piramal Healthcare Limited Acquires Molecular Imaging Development Portfolio of Bayer Pharma 3Lilly's John Lechleiter Becomes PhRMA Board Chairman; Robert J. Hugin, Ian Read Assume New Posts 2Lilly's John Lechleiter Becomes PhRMA Board Chairman; Robert J. Hugin, Ian Read Assume New Posts 3
Used for placement of choledochoscopes, cholangiography catheters and other instruments. Supplied sterile in peel-open packages. Intended for one-time use....
... for cholangiography and bile ... Dual lumen catheter design ... imaging and wire basket ... Supplied sterile in peel-open ...
... the MAMMOTOME® HH (Hand Held) ... procedure using ultrasound imaging for ... to locate breast abnormalities, you ... map the area you will ...
... Provides a more occlusive wrap than ... where wound transudate must be contained. Predictable ... be inert, nonantigenic, and nonpyrogenic. ,VICRYL (polyglactin ... synthetic absorbable copolymer of glycolide and lactide, ...
Medicine Products: